Skip to main content
SpringerLink
Log in

Botulinum Toxin for the Management of Bladder Dysfunction

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

This review highlights a recent innovation in the medical treatment of detrusor overactivity (DO). Anticholinergics are usually the gold standard to treat bladder overactivity. Adverse effects and lack of efficacy are the two main causes for considering alternative treatments. Until recently, invasive surgery (mainly bladder augmentation) was the only available treatment option for patients with intractable DO. This article considers botulinum toxin type A (BTX-A) injection as an alternative treatment to surgery in patients with DO who do not respond to anticholinergic therapy. To identify papers for inclusion in this review, we searched PubMed with the keywords ‘botulinum toxin’, ‘overactive bladder’, ‘urinary incontinence’ and ‘neurogenic bladder’ for the years 2000–5. Review articles were not included. Abstracts were cited only if they contained important new information. Experimental animal studies and articles or book chapters related to the use of botulinum toxin for other indications (such as achalasia and cervical dystonia) were analysed with regard to the mechanisms of action of botulinum toxin.

From this review, it appears that BTX-A injection into the detrusor muscle is a very effective method for treating urinary incontinence secondary to neurogenic detrusor overactivity (NDO), as well as urinary incontinence due to idiopathic overactive bladder (IDO). In both conditions, the duration of effect seems to be at least 6 months. Overall success rates seem to be similar in both patient populations. For NDO, only one evidence-based medicine level 1 study is available, whereas for IDO, only evidence-based medicine level 3 or 4 studies have been published. Particularly in this latter indication, injection technique and outcome parameters vary from study to study and need to be standardised. Without randomised controlled studies aimed at comparing different techniques and dosages, it remains difficult to decide what technique is optimal for treating patients with IDO who are not willing to perform clean intermittent self-catheterisation (CISC). Therefore, studies that compare different dosages and techniques with the risk of needing CISC in regard to the duration of the effect are mandatory. As more studies of repeated injections have been published, it appears that, at least at medium follow-up, the toxin remains as effective as after the first injection, and there is no evidence of change in bladder compliance or detrusor fibrosis. However, long-term observational studies are necessary to assess these last points. Finally, the commonly reported dose appears to be well tolerated, since few adverse effects have been reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167–78

    Article  PubMed  Google Scholar 

  2. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999 Jun; 161(6): 1809–12

    CAS  Google Scholar 

  3. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 Mar; 57(3): 414–21

    Article  PubMed  Google Scholar 

  4. Wojdan A, Freeden C, Woods M, et al. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J Pharmacol Exp Ther 1999 Jun; 289(3): 1410–8

    PubMed  CAS  Google Scholar 

  5. Igawa Y, Yamazaki Y, Takeda H, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol 2001 Jan; 165(1): 240–4

    Article  PubMed  CAS  Google Scholar 

  6. Noble AJ, Chess-Williams R, Couldwell C, et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol 1997 Jan; 120(2): 231–8

    Article  PubMed  CAS  Google Scholar 

  7. Kamo I, Imai S, Okanishi S, et al. Possible site of action of TAK-637, a tachykinin NK (1) receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol 2000 Aug 4; 401(2): 235–40

    Article  PubMed  CAS  Google Scholar 

  8. Enzelsberger H, Helmer H, Kurz C. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 1995 Nov; 102(11): 929–30

    Article  PubMed  CAS  Google Scholar 

  9. Fowler CJ, Jewkes D, McDonald WI, et al. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992 May 16; 339(8803): 1239

    Article  PubMed  CAS  Google Scholar 

  10. Cruz F, Guimaraes M, Silva C, et al. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997 Aug 30; 350(9078): 640–1

    Article  PubMed  CAS  Google Scholar 

  11. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986; 26: 427–53

    Article  PubMed  CAS  Google Scholar 

  12. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999 Oct 22; 53(7): 1439–46

    Article  PubMed  CAS  Google Scholar 

  13. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999 Oct 22; 53(7): 1431–8

    Article  PubMed  CAS  Google Scholar 

  14. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997 Jul; 49(1): 189–94

    Article  PubMed  CAS  Google Scholar 

  15. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 3–13

    Google Scholar 

  16. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000 Mar 2; 342(9): 665

    Article  PubMed  CAS  Google Scholar 

  17. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000 Sep; 164 (3 Pt 1): 692–7

    Article  PubMed  CAS  Google Scholar 

  18. Dickson EC, Shevky R. Studies on manner in which the toxin of clostridium botulinum acts upon the body: I. The effect upon the autonomic nervous system. J Exp Med 1923; 37: 711–31

    CAS  Google Scholar 

  19. Annese V, Basciani M, Borrelli O, et al. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 1998 Nov; 21(11): 1540–2

    Article  PubMed  CAS  Google Scholar 

  20. Carpenter FG. Motor responses of the response of the urinary bladder and skeletal muscle in botulinum toxin intoxicated rats. J Physiol 1967; 1988: 1–11

    Google Scholar 

  21. MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982 Apr; 7(4): 997–1006

    Article  PubMed  CAS  Google Scholar 

  22. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003 May; 169(5): 1896–900

    Article  PubMed  CAS  Google Scholar 

  23. Smith CP, Fraser MO, Bartho L, et al. Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions [abstract]. J Urol 2002; 167(4): 249

    Article  Google Scholar 

  24. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005 Sep; 174(3): 977–82

    Article  PubMed  CAS  Google Scholar 

  25. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81(6): 801–10

    Article  PubMed  CAS  Google Scholar 

  26. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10(5): 283–9

    Article  PubMed  CAS  Google Scholar 

  27. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (6A Suppl.): 90–6

    Article  PubMed  CAS  Google Scholar 

  28. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002; 41(6): 588–95

    Article  PubMed  CAS  Google Scholar 

  29. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004 Apr; 45(4): 510–5

    Article  PubMed  CAS  Google Scholar 

  30. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005 Jul; 174(1): 196–200

    Article  PubMed  CAS  Google Scholar 

  31. Patki P, Hamid R, Arumugam K, et al. Botulinum-A toxin (Dysport) in the treatment of drug resistant neurogenic detrusor overactivity following traumatic spinal cord injury. BJU Int. In Press

  32. Del Popolo G, Li Marzi V, Panariello G, et al. English botulinum, toxin-A in the treatment of neurogenic detrusor overactivity [abstract]. Neurourol Urodyn 2003; 22(5): 498

    Google Scholar 

  33. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004 Jul; 172(1): 240–3

    Article  PubMed  CAS  Google Scholar 

  34. Giannantoni A, Merini E, Di Stasi SM, et al. New therapeutic option for refractory neurogenic detrusor overactivity. Minerva Urol Nephrol 2004; 56: 78–87

    Google Scholar 

  35. Kennelly M, Kang J. Botulinum-A toxin injection into the detrusor as treatment for refractory detrusor hypperreflexia. Top Spinal Cord Inj Rehabil 2003; 8: 46–53

    Article  Google Scholar 

  36. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004 May; 63(5): 868–72

    Article  PubMed  Google Scholar 

  37. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005 Jul; 66(1): 94–8

    Article  PubMed  Google Scholar 

  38. Hajebrahimi S, Altaweel W, Cadoret J, et al. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 2005 Feb; 12(1): 2543–6

    PubMed  CAS  Google Scholar 

  39. Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 2005 Nov; 86(11): 2114–8

    Article  PubMed  Google Scholar 

  40. Harper M, Popat RB, Dasgupta R, et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003 Aug; 92(3): 325–6

    Article  PubMed  CAS  Google Scholar 

  41. Loch A, Loch T, Osterhage J, et al. Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence [abstract]. Eur Urol Suppl 2003; 2(1): 172

    Article  Google Scholar 

  42. Bagi P, Biering-Sorensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 2004; 38(6): 495–8

    Article  PubMed  CAS  Google Scholar 

  43. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005 May; 47(5): 653–9

    Article  PubMed  CAS  Google Scholar 

  44. Kessler KR, Benecke R. The EBD test: a clinical test for the detection of antibodies to botulinum type A. Mov Disord 1997; 12(9): 95–9

    Article  PubMed  CAS  Google Scholar 

  45. Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 2005 Sep; 19(7): 880–2

    Article  PubMed  Google Scholar 

  46. Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005 Sep; 174(3): 984–9

    Article  PubMed  CAS  Google Scholar 

  47. Schulte-Baukloh H, Michael T, Schobert J, et al. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002 Mar; 59(3): 325–7

    Article  PubMed  CAS  Google Scholar 

  48. Schulte-Baukloh H, Michael T, Sturzebecher B, et al. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003 Jul; 44(1): 139–43

    Article  PubMed  CAS  Google Scholar 

  49. Riccabona M, Koen M, Schindler M, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004 Feb; 171 (2 Pt 1): 845–8

    Article  PubMed  CAS  Google Scholar 

  50. Corcos J, Al-Taweed W, Robichaud C. Botulinum toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomeningocele [abstract]. J Urol 2004; 171: 181

    Google Scholar 

  51. Hernandez RD, Hurwitz RS, Foote JE, et al. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 1994 Nov; 152 (5 Pt 1): 1582–5

    PubMed  CAS  Google Scholar 

  52. Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005 Oct; 66(4): 865–70

    Article  PubMed  Google Scholar 

  53. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005 May; 192(5): 1735–40

    Article  PubMed  CAS  Google Scholar 

  54. Schulte-Baukloh H, Weiss C, Schobert J, et al. Subjective patient satisfaction after injection of botulinum-a toxin in detrusor overactivity [in German]. Aktuelle Urol 2005 Jun; 36(3): 230–3

    Article  PubMed  CAS  Google Scholar 

  55. Sahai A, Khan M, Smith K, et al. Botulinum toxin for patients with detrusor overactivity: early results from a randomised, double blind placebo-controlled trial [abstract]. Eur Urol 2005; Suppl. 5: 118

    Google Scholar 

  56. Rajkumar GN, Small DR, Mustafa AW, et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005 Oct; 96(6): 848–52

    Article  PubMed  CAS  Google Scholar 

  57. Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003 Dec; 14(6): 424–6

    Article  PubMed  Google Scholar 

  58. Radziszewski P, Borkowski A. Botulinum toxin type A intravesical injections for instable bladder overactivity [abstract]. Eur Urol Suppl 2002; 1(1): 134

    Article  Google Scholar 

  59. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004 Dec; 172 (6 Pt 1): 2316–20

    Article  PubMed  CAS  Google Scholar 

  60. Rapp DE, Lucioni A, Katz EE, et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004; 63(6): 1071–5

    Article  PubMed  Google Scholar 

  61. Kessler TM, Danuser H, Schumacher M, et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24(3): 231–6

    Article  PubMed  CAS  Google Scholar 

  62. Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005 Dec; 48(6): 984–90

    Article  PubMed  Google Scholar 

  63. Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005 Nov; 174(5): 1873–7

    Article  PubMed  CAS  Google Scholar 

  64. Schmid DM, Sauermann P, Werner M, et al. Experience of 100 cases treated with botulinum-A toxin Injections into the detrusor muscle for idiopathic overactive bladder refractory to anticholinergics. J Urol 2006 Jul; 176(1): 177–85

    Article  PubMed  CAS  Google Scholar 

  65. Schmid DM, Schurch B, John H, et al. Botulinum toxin injection to treat overactive bladder [abstract]. Eur Urol 2004; Suppl. 3(2): 131

    Google Scholar 

  66. Verleyen P, Hoebeke P, Raes P, et al. The use of botulinum toxin A in children with a non-neurogenic overactive bladder: a pilot study. BJU Int 2004; 93 Suppl.: 69–72

    Google Scholar 

  67. Dykstra DD, Pryor J, Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil 2003 Sep; 84(9): 1399–400

    Article  PubMed  Google Scholar 

  68. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004 Feb; 171 (2 Pt 1): 804

    Article  PubMed  Google Scholar 

  69. Pistolesi D, Selli C, Rossi B, et al. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004 Feb; 171 (2 Pt 1): 802–3

    Article  PubMed  CAS  Google Scholar 

  70. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001 Apr; 248 Suppl. 1: 3–10

    Article  Google Scholar 

  71. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29(1): 7–13

    Article  PubMed  Google Scholar 

  72. Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest 2002 Aug–Nov; 31(3–4): 247–62

    Article  PubMed  CAS  Google Scholar 

  73. Rosenberg JS, Middlebrook JL, Atassi MZ. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest 1997 Jun; 26(4): 491–504

    Article  PubMed  CAS  Google Scholar 

  74. Goschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies: therapeutic consequences. Exp Neurol 1997 Sep; 147(1): 96–102

    Article  PubMed  CAS  Google Scholar 

  75. Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A: resistant patients. Mov Disord 1996 Mar; 11(2): 181–4

    Article  PubMed  CAS  Google Scholar 

  76. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45(9): 1743–6

    Article  PubMed  CAS  Google Scholar 

  77. Schurch B, Corcos J. Botulinum toxin injections for paediatric incontinence. Curr Opin Urol 2005 Jul; 15(4): 264–7

    Article  PubMed  Google Scholar 

  78. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003 Apr 8; 60(7): 1186–8

    Article  PubMed  CAS  Google Scholar 

  79. Kerner J. Neue Beobachtungen uber die in Würtemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuss geraucheter Würste. Tübingen: Osiander, 1820

    Google Scholar 

  80. Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den tierischen Orgismus; ein Beytrag zur Untersuchung des in Verdorbenen Wursten giftig wirkenden Stoffes. Stuttgart: Cotta, 1822

    Google Scholar 

  81. Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991 Nov; 41(11): 1800–5

    Article  PubMed  CAS  Google Scholar 

  82. Printer MJ, Vanden Noven S, Muccio D, et al. Axotomy-like changes in cat motorneuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission. J Neurosci 1991; 11: 657–66

    Google Scholar 

  83. de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999 Mar 16; 96(6): 3200–5

    Article  PubMed  Google Scholar 

  84. Grosse J, Kramer G, Schurch B, et al. Repeat injections of botulinum-A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance. Neurourol Urodyn 2002; 21(4): 386–287

    Google Scholar 

  85. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004 Dec; 46(6): 784–91

    Article  PubMed  CAS  Google Scholar 

  86. Borodic GE, Ferrante R, Pearce LB, et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994 Jan; 9(1): 31–9

    Article  PubMed  CAS  Google Scholar 

  87. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3(4): 333–5

    Article  PubMed  CAS  Google Scholar 

  88. Malnick SD, Metchnik L, Somin M, et al. Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol 2000 Nov; 95(11): 3333–4

    Article  PubMed  CAS  Google Scholar 

  89. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999 Apr; 246(4): 265–74

    Article  PubMed  CAS  Google Scholar 

  90. Del Popolo G. Botulinum-A toxin in the treatment of detrusor hyperreflexia [abstract]. Neurourol Urodyn 2001; 20: 522

    Google Scholar 

  91. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002 Nov; 40(11): 599–600

    Article  PubMed  CAS  Google Scholar 

  92. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990 Jan; 71(1): 24–6

    PubMed  CAS  Google Scholar 

  93. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002 Apr; 72(4): 459–62

    PubMed  CAS  Google Scholar 

  94. Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998; 78: 231–5

    PubMed  Google Scholar 

  95. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003 Aug; 44(2): 165–74

    Article  PubMed  CAS  Google Scholar 

  96. Kalsi V, Popat R, Odyemi I, et al. P. A cost effectiveness model for botulinum neurotoxin type A (BoNT/A) in the treatment of patients with detrusor overactivity: preliminary results. BJU Int 2005; 95 Suppl. 5: 60–1

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-Urology, Swiss Paraplegic Center, Balgrist University Hospital, Forchstrasse 340, Zurich, 8008, Switzerland

    Brigitte Schurch

Authors
  1. Brigitte Schurch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brigitte Schurch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schurch, B. Botulinum Toxin for the Management of Bladder Dysfunction. Drugs 66, 1301–1318 (2006). https://doi.org/10.2165/00003495-200666100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666100-00001

Keywords

Search

Navigation